ONWARD® MEDICAL

Investor Webcast
2026 Q3 Results

November 3, 2026

Forward Looking Statements

This Presentation may include statements, including the Company's financial and operational medium-term objectives, that may be deemed to be "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "aims", "forecasts", "continues", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions.

Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view concerning future events and are subject to risks relating to future events and other risks, uncertainties, and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth, or strategies. Forward-looking statements speak only as of the date they are made.

Speaking Today



Dave Marver
Chief Executive Officer



Ali Kiboro
Chief Financial Officer



Shari O'Quinn
Chief Clinical, Regulatory & Quality Officer

Q3 2026 Business Updates

Sustained commercial momentum and strong clinical execution

Q3 & YTD Highlights



Commercial traction

88 ARC^{EX} Systems

sold or supplied via paid evaluation in Q3 2026



Empower BP global pivotal study

31 participants enrolled and 16 centers activated to date



Pipeline advancement

across several **ARC^{IM} clinical feasibility programs**



Financial highlights

€2.5M in revenue

in Q3 2026


ARC EX
Program
ready

ARC^{EX} Commercial Uptake

88 ARC^{EX} Systems sold or under paid evaluation in Q3 2026

88 ARC^{EX} Systems sold or supplied via paid evaluation

+120% Year-over-year growth in units

>150 US clinics and VA facilities equipped

>170 Clinics penetrated worldwide





Start with VA and self-pay, while establishing claims history to unlock broad reimbursement

ARC^{EX} US Home Use Reimbursement Strategy

Start where payment exists

Ongoing since Q1 2026

- **VA**
- **Self-pay**

Initiate case-by-case submissions for other payors

Ongoing since Q2 2026

- Benefit category confirmed as DME and HCPCS code assigned
- Case-by-case submissions ongoing to build claim history with Medicare, commercial payors and workers' compensation

Unlock broad reimbursement

Ongoing to 2+ years

Ongoing clinical evidence development to secure broad payor coverage

Establish claims history and collect additional data (e.g. real-world evidence, additional clinical study) to support future reimbursement decisions


ARC IM
< 3 cm
1....8
9....16
ONWARD
ARC IM
BI Y27852

Pipeline Overview

Pre-clinical
Human PoC
Clinical feasibility
Pivotal
Commercial

Platform		Indication	FDA Breakthrough Device Designation	Current stage
ARC EX		Upper limb	✓	●●●●●
		Bladder/bowel	✓	↕ Investigator initiated studies
		Stroke upper limb		
ARC IM		Blood pressure	✓	●●●●○
		Mobility	✓	●●●○○
		Parkinson's – Mobility		●●●○○
		Parkinson's – Blood pressure		●●○○○
		Bladder	✓	●●○○○
ARC BCI		Mobility	✓	●●●○○
		Upper limb		●●●○○
		Stroke – Upper limb		●○○○○

Note: The company may modify the pipeline based on clinical progress and marketplace considerations

[1] *BDD = FDA Breakthrough Device Designation*

Empower BP Pivotal Trial Update

31

participants enrolled

16

clinical sites
actively recruiting





2026 | 2027 | 2028 | 2029

Enrollment and primary endpoint completion → **Follow-up**

◆ Interim analysis

◆ Anticipated commercial launch

As of Nov 2026

Meaningful progress across ARC^{IM} clinical feasibility programs

Other Clinical Milestones

SCI Mobility
EIGER study

Innosuisse

First implants in both the chronic **and subacute** cohorts evaluating ARC^{IM} Therapy to restore mobility

SCI Bladder
ReeVoid study

Christopher & Dana Reeve Foundation
TODAY'S CARE. TOMORROW'S CURE.

First-in-human use of ARC^{IM} Therapy to restore bladder control

Parkinson's blood pressure
PD HemON study

U.S. Department of Defense

Two additional participants received ARC^{IM} Therapy to address blood pressure instability in Parkinson's disease



Q3 2026 Results

Q3 2026 Financial Highlights

€2.5M in revenue and cash balance of €73.4M as of Sep 30, 2026

Revenue
€2.5M in Q3 2026[1]

Burn
€8.1M[2] used during Q3 2026

Current Cash Balance
€73.4M net cash[3] as of 30 Sep 2026

[1] Revenue includes grant and other income, [2] Cash burn includes proceeds from debt refinancing, [3] Net cash is defined as the sum of cash and cash equivalents and fixed term deposits included in the current assets as included in consolidated statement of financial position in the Financial Statements

2026 Outlook

Several important catalysts expected in the next 12 months

Upcoming Milestones and News Flow

ARC^EX ARC^IM ARC^BCI

ARC^EX
First commercial clinic sale (EU)
Hand sensation & strength
Completed

ARC^EX
First commercial home use sale (US)
Hand sensation & strength
Completed

ARC^EX
First commercial clinic sale (ROW)
Hand sensation & strength
Completed

ARC^EX
First commercial home use sale (EU)
Hand sensation & strength

ARC^IM
First participant enrollment
Empower BP pivotal study – Blood pressure
Completed

ARC^IM *GRANT FUNDED*
Additional implants
Parkinson's disease
Completed

ARC^IM *GRANT FUNDED*
Additional implants
Mobility
Completed

ARC^IM *GRANT FUNDED*
First-in-human[2]
Bladder
Completed

ARC^IM
Top line interim analysis
Empower BP pivotal study – Blood pressure

ARC^BCI *GRANT FUNDED*
Additional implants[3]
SCI mobility
Completed

ARC^BCI *GRANT FUNDED*
Additional implants[3]
SCI upper limb

ARC^BCI *GRANT FUNDED*
First implant[3]
Stroke upper limb

Note: ARC^IM and ARC^BCI are investigational devices, not available for commercial use. The ONWARD® Medical ARC^EX® System is cleared for use in the United States and Europe.

[1] *Funded by Michael J. Fox Foundation for Parkinson's Research grant*
[2] *Funded by Christopher & Dana Reeve Foundation grant*
[3] *Funded by European Innovation Council, Christopher & Dana Reeve Foundation, UNIL Foundation grants and ONWARD contributions*

Q&A

Thank you!

ONWARD®
MEDICAL